A 2-part Study to Investigate the Dose-ranging Pharmacokinetics and Tolerability, Followed by the Efficacy and Safety of Cannabidiol (GWP42003-P) in Children and Young Adults With Drug Resistant Epilepsy
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 17 Apr 2017
At a glance
- Drugs Cannabidiol (Primary)
- Indications Epilepsy
- Focus Therapeutic Use
- 08 Jan 2016 Planned End Date changed from 1 Dec 2015 to 1 Dec 2018 as reported by ClinicalTrials.gov record.
- 08 Jan 2016 Planned primary completion date changed from 1 Jun 2015 to 1 Jun 2018 as reported by ClinicalTrials.gov record.
- 08 Jan 2016 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.